MG
BCYC

Marex Group’s Bicycle Therapeutics BCYC Stock Holding History

Marex Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$534K Buy
115,000
+36,594
+47% +$209K ﹤0.01% 608
2025
Q4 		$555K Buy
+78,406
New +$578K ﹤0.01% 536

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marex Group's BCYC Position: Q1 2026 in Review

Marex Group increased its Bicycle Therapeutics (BCYC) stake by 47% in Q1 2026, buying an estimated $209K and bringing the position to 115,000 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Marex Group first reported a position in BCYC in Q4 2025 and has held it in 2 quarters since. The position peaked at $555K in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Marex Group held 115,000 shares of Bicycle Therapeutics worth $534K as of Q1 2026.
  • Marex Group bought 36,594 Bicycle Therapeutics shares in Q1 2026, an estimated $209K.
  • Bicycle Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #608 holding.
  • Marex Group first reported a position in Bicycle Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Marex Group's Bicycle Therapeutics position peaked at $555K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.